Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market was valued at USD 0.91 Billion in 2022 and is projected to reach USD 1.32 Billion by 2030, growing at a CAGR of 5.1% from 2024 to 2030.
Japan's DPP-4 inhibitors market has experienced significant growth, reflecting the nation's proactive approach to managing type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance insulin secretion and suppress glucagon release, have become a cornerstone in T2DM treatment. This article delves into the types of DPP-4 inhibitors available in Japan and the evolving requirements from the pharmaceutical industry.
Overview of DPP-4 Inhibitors in Japan
Sitagliptin (Januvia): Introduced by Merck & Co., sitagliptin was among the first DPP-4 inhibitors approved in Japan. Its efficacy in lowering blood glucose levels made it a popular choice among healthcare professionals.
Omarigliptin (Marizev): Approved in 2015, omarigliptin offers a once-weekly dosing regimen, providing convenience for patients and potentially improving adherence. Japan was the first country to approve this formulation. citeturn0search0
Teneligliptin (Tenelia): Originating from Japan, teneligliptin received approval in 2012. Its potent and sustained action has made it effective in lowering both postprandial and fasting blood glucose levels with once-daily administration. citeturn0search3
Linagliptin (Tradjenta): Approved in 2011, linagliptin is notable for its safety profile, especially in patients with renal or hepatic impairment, as it does not require dosage adjustments. citeturn0search4
Market Dynamics and Industry Requirements
The Japanese market has seen a shift towards more patient-centric therapies. The approval of once-weekly DPP-4 inhibitors like omarigliptin addresses the need for simplified treatment regimens, aiming to enhance patient compliance. citeturn0search0
In 2023, Japan approved its first generic version of a DPP-4 inhibitor for sitagliptin, signaling a move towards more cost-effective treatments. This approval reflects the industry's response to the growing demand for affordable diabetes medications. citeturn0search2
Pharmaceutical companies are now focusing on:
Innovative Formulations: Developing drugs with extended dosing intervals to improve adherence.
Comprehensive Safety Profiles: Ensuring efficacy in patients with comorbid conditions like renal or hepatic impairments.
Cost-Effectiveness: Balancing innovation with affordability to meet the needs of a broader patient population.
As the prevalence of T2DM continues to rise, the Japanese pharmaceutical industry must adapt by offering diverse and accessible treatment options. The recent approval of generic DPP-4 inhibitors and the development of novel formulations underscore the industry's commitment to addressing the evolving needs of patients and healthcare providers.
Get an In-Depth Research Analysis of the Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market Size And Forecast [2025-2032]
AstraZeneca
Boehringer
Eli Lilly
Merck
Mitsubishi Tanabe Pharma
Novartis
Takeda
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin
Oral Tablets
Oral Solutions
Type 2 Diabetes Management
Combination Therapy with Other Antidiabetics
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Hospitals
Clinics
Home Healthcare Settings
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market Research Analysis
1. Introduction of the Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market, By Type
6. Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market, By Application
7. Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan DPP IV Inhibitors (DPP-4 Inhibitors) Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/